Board of Directors

Paul Buckman, Chairman

Mr. Buckman serves as Chairman of the Board of Directors of NeuroOne. He is currently the General Manager of TMVR for LivaNova PLC. Prior to joining LivaNova, Mr. Buckman served as Chief Executive Officer of Conventus Orthopaedics, a Minnesota-based company specializing in peri-articular bone fracture fixation. Prior to LivaNova, Mr. Buckman was Chief Executive Officer of Sentreheart, a medical technology company focused on closure of various anatomic structures. Previously, Mr. Buckman served as Chief Executive Officer and Chairman of Pathway Medical Technologies, a medical device company focused on treatment of peripheral arterial disease. From 2006 to 2008, Mr. Buckman served as Chief Executive Officer of Devax, a developer and manufacturer of drug eluting stents. From 2004 to 2006, Mr. Buckman served as President of the Cardiology Division of St. Jude Medical. From 2001 to 2004, Mr. Buckman was the Chairman of the Board of Directors and Chief Executive Officer of ev3, a Minnesota-based medical device company focused on endovascular therapies that Mr. Buckman founded and developed into an $80 million business. Mr. Buckman has worked in the medical device industry for over 30 years, including ten years at Scimed Life Systems and Boston Scientific Corporation. Mr. Buckman received a Master’s degree in Business Administration and Finance and a B.A. degree in Business Administration from Western Michigan University.

Jeffrey Mathiesen

Mr. Mathiesen serves as a member of the board of directors of NeuroOne. He currently serves as the Chief Financial Officer of Gemphire Therapeutics, a publicly-held clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic disorders, a position he has held since 2015. Prior to joining Gemphire, Mr. Mathiesen served as Chief Financial Officer of Sunshine Heart, a publicly traded medical device company. From 2005 to 2010, Mr. Mathiesen served as Vice President and Chief Financial Officer of Zareba Systems, a manufacturer and marketer of medical products, perimeter fencing and security systems, which was purchased by Woodstream Corporation in 2010. Mr. Mathiesen serves as a director, audit committee chairman and nominating and governance committee member of Sun BioPharma, a publicly traded clinical stage biopharmaceutical company that develops therapies for pancreatic diseases. Mr. Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.

Suraj Kalia

Mr. Kalia serves as a member of the board of directors of NeuroOne. He currently serves as a Managing Director and Senior Research Analyst at Northland Capital Markets, where he covers the medical technology sector, after rejoining the firm in August 2012. His previous positions include Managing Director and Senior Medical Device Analyst at Rodman & Renshaw Capital Group, Senior Vice President at Madison Williams and Company LLC, Senior Research Analyst at Piper Jaffray Companies, and Project Manager at Entegris as part of the Business Development & Engineering groups. Mr. Kalia has served as a member of the Advisory Board of Levitronix, LLC from 2009 till its acquisition by Thoratec Corp in 2011. He has more than 18 years of experience working in the financial and health care industries. Mr. Kalia has also served as an Adjunct Professor of Finance and taught MBA level courses on Investment Theory and Mergers & Acquisitions at University of St. Thomas. He received a Master’s of Business Administration degree in Finance from the University of St. Thomas in Minneapolis, a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology in Bombay, India and a Master’s degree in Chemical Engineering from Stevens Institute of Technology in Hoboken, N.J.

Dave Rosa, President and Chief Executive Officer

Mr. Rosa serves on the board of directors of NeuroOne and is an entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early stage medical device companies, Mr. Rosa’s background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University, and a BS in Commerce and Engineering from Drexel University.